Modulating regulatory T cell function in Juvenile Idiopathic Arthritis with Vitamin B3 (nicotinamide): a phase I/II trial focusing on safety and feasibility aspects in children with JIA. - B-Vit in JIA trial

niversitair Medisch Centrum Utrecht0 个研究点目标入组 45 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•- Patients with a diagnosis of oligo-articular or poly-articular JIA with active disease in 1 or multiple joints and an indication for intra-articular corticosteroid injection.
•- Age between 4 to 18 years
•- At the moment of inclusion, not on non-biological DMARD (Methotrexate) treatment or on stable DMARD treatment (at least 3 months of stable Methotrexate use).

•- no informed consent possible by patient/parents or caregivers
•- participation in other interventional trials
•- Treatment with biological DMARD
•- Recently started treatment with non-biological DMARD (Methotrexate). Defined as treatment for a period less than 3 months.
•- Use of systemic corticosteroids
•- Relevant co morbidity: raised liver enzymes (>2x upper limit) and/or evidence of bone marrow failure (pancytopenia based upon full blood count).

发起方

niversitair Medisch Centrum Utrecht